Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer

Cancer Medicine

Volumn 6, Issue 5, 2017, Pages 962-974

  Hu, Wenwei ^a   Yang, Yang ^b   Zhang, Longzhen ^a   Yin, Jianxin ^a   Huang, Jingwei ^a   Huang, Lei ^a   Gu, Hua ^a   Jiang, Gening ^b   Fang, Jianmin ^a,c,d  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI PULMONARY HOSPITAL   (China)

^c SOOCHOW UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Circulating cell free DNA; lung cancer; relapse; surgery

Indexed keywords

CIRCULATING FREE DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COPY NUMBER VARIATION; DNA DETERMINATION; EFGR GENE; GENE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; ADULT; AGED; BLOOD; FEMALE; GENE DOSAGE; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DNA, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE;

EID: 85017097475     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.980     Document Type: Article

References (56)

1. Siegel, R. L., K. D. Miller, and A. Jemal. 2015. Cancer Statistics, 2015. Ca-Cancer J Clin. 65:5–29.
2. Uzel, E. K., and U. Abacioglu. 2015. Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? Balk Med J. 32:8–16.
3. Cho, S., S. W. Sung, S. Jheon, and J. H. Chung. 2008. Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis. Lung 186:411–419.
4. Punnoose, E. A., S. Atwal, W. Q. Liu, R. Raja, B. M. Fine, B. G. M. Hughes, et al. 2012. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase ii clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18:2391–2401.
5. Bai, H., Z. J. Wang, K. N. Chen, J. Zhao, J. J. Lee, S. H. Wang, et al. 2012. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J. Clin. Oncol. 30:3077–3083.
6. Thierry, A. R., F. Mouliere, S. El Messaoudi, C. Mollevi, E. Lopez-Crapez, F. Rolet, et al. 2014. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 20:430–435.
7. Schwarzenbach, H., D. S. B. Hoon, and K. Pantel. 2011. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11:426–437.
8. Taniguchi, K., J. Uchida, K. Nishino, T. Kumagai, T. Okuyama, J. Okami, et al. 2011. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17:7808–7815.
9. Douillard, J. Y., G. Ostoros, M. Cobo, T. Ciuleanu, R. Cole, G. McWalter, et al. 2014. Gefitinib treatment in EGFR mutated caucasian NSCLC circulating-free tumor DNA as a surrogate for determination of egfr status. J. Thorac. Oncol. 9:1345–1353.
10. Haber, D. A., and V. E. Velculescu. 2014. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 4:650–661.
11. Roma, C., C. Esposito, A. M. Rachiglio, R. Pasquale, A. Iannaccone, N. Chicchinelli, et al. 2013. Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed. Res. Int. 2013:385087.
12. Dufresne, A., L. Alberti, M. Brahmi, S. Kabani, H. Philippon, D. Perol, et al. 2014. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. BMC Cancer 14:623.
13. Richter, A., F. Grieu, A. Carrello, B. Amanuel, K. Namdarian, A. Rynska, et al. 2013. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci. Rep.-UK. 3:1659.
14. Spindler, K. L. G., N. Pallisgaard, I. Vogelius, and A. Jakobsen. 2012. Quantitative cell-free DNA, KRAS, and BRAF Mutations in Plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin. Cancer Res. 18:1177–1185.
15. Brocki, B. C., J. Andreasen, L. R. Nielsen, V. Nekrasas, A. Gorst-Rasmussen, and E. Westerdahl. 2014. Short and long-term effects of supervised versus unsupervised exercise training on health-related quality of life and functional outcomes following lung cancer surgery - A randomized controlled trial. Lung Cancer 83:102–108.
16. Yu, J. B., P. R. Soulos, L. D. Cramer, R. H. Decker, A. W. Kim, and C. P. Gross. 2015. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer 121:2341–2349.
17. Verstegen, N. E. 2013. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis (vol 24, pg 1543, 2013). Ann. Oncol. 24:2466.
18. Bertolaccini, L., A. Terzi, F. Ricchetti, and F. Alongi. 2015. Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? Ann. Trans. Med. 3:25.
19. Martinez, P., A. Martinez-Marti, A. Navarro, S. Cedres, and E. Felip. 2014. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate? Lung Cancer 84:97–100.
20. Udyavar, A. R., M. Hoeksema, K. Diggins, J. Irish, P. P. Massion, and V. Quaranta. 2014. Phenotypic plasticity and heterogeneity in small cell lung cancer (SCLC): Novel molecular subtypes and potential for targeted therapy. Clin. Cancer Res. 20:B27.
21. Diaz, L. A., R. T. Williams, J. Wu, I. Kinde, J. R. Hecht, J. Berlin, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540.
22. Misale, S., R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, et al. 2012. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532–536.
23. Dawson, S. J., D. W. Y. Tsui, M. Murtaza, H. Biggs, O. M. Rueda, S. F. Chin, et al. 2013. Analysis of circulating tumor DNA to monitor metastatic breast cancer. New Engl. J. Med. 368:1199–1209.
24. Oxnard, G. R., C. P. Paweletz, Y. A. Kuang, S. L. Mach, A. O'Connell, M. M. Messineo, et al. 2014. Noninvasive detection of response and resistance in egfr-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20:1698–1705.
25. Crowley, E., F. Di Nicolantonio, F. Loupakis, and A. Bardelli. 2013. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10:472–484.
26. Lee, A. J. X., D. Endesfelder, A. J. Rowan, A. Walther, N. J. Birkbak, P. A. Futreal, et al. 2011. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 71:1858–1870.
27. Charles, J. P., J. Fuchs, M. Hefter, J. B. Vischedyk, M. Kleint, and F. Vogiatzi, et al. 2014. Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. Nat. Commun. 5:3981.
28. Qiu, M. T., J. Wang, Y. T. Xu, X. X. Ding, M. Li, F. Jiang, et al. 2015. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidem. Biomar. 24:206–212.
29. Qian, X., J. Liu, Y. Sun, M. Wang, H. Lei, G. Luo, et al. 2016. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer. Oncotarget 7:29154–29165.
30. Zhang, J. J., J. Fujimoto, J. H. Zhang, D. C. Wedge, X. Z. Song, J. X. Zhang, et al. 2014. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346:256–259.
31. de Bruin, E. C., N. McGranahan, R. Mitter, M. Salm, D. C. Wedge, L. Yates, et al. 2014. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346:251–256.
32. Bunn, P. A., F. R. Hirsch, and D. L. Aisner. 2014. Is there clinical value to prognostic signatures in early-stage NSCLC? Clin. Cancer Res. 20:1727–1729.
33. Massarelli, E., M. Varella-Garcia, X. M. Tang, A. C. Xavier, N. C. Ozburn, D. D. Liu, et al. 2007. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 13:2890–2896.
34. Jackman, D. M., V. A. Miller, L. A. Cioffredi, B. Y. Yeap, P. A. Janne, G. J. Riely, et al. 2009. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin. Cancer Res. 15:5267–5273.
35. West, H., R. Lilenbaum, D. Harpole, A. Wozniak, and L. Sequist. 2009. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J. Thorac. Oncol. 4:S1029–S1039.
36. Bell, D. W., T. J. Lynch, S. M. Haserlat, P. L. Harris, R. A. Okimoto, B. W. Brannigan, et al. 2005. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23:8081–8092.
37. Hirsch, F. R., M. Varella-Garcia, R. Dziadziuszko, Y. Xiao, S. Gajapathy, M. Skokan, et al. 2008. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a Phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin. Cancer Res. 14:6317–6323.
38. Ocana, A., L. Diez-Gonzalez, D. C. Garcia-Olmo, A. J. Templeton, F. Vera-Badillo, M. Jose Escribano, et al. 2016. Circulating DNA and Survival in Solid Tumors. Cancer Epidemiol. Biomarkers Prev. 25:399–406.
39. Szpechcinski, A., J. Chorostowska-Wynimko, R. Struniawski, W. Kupis, P. Rudzinski, R. Langfort, et al. 2015. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br. J. Cancer 113:476–483.
40. Uramoto, H., and F. Tanaka. 2012. Prediction of recurrence after complete resection in patients with NSCLC. Anticancer Res. 32:3953–3960.
41. Choi, P. J., S. S. Jeong, and S. S. Yoon. 2013. Prognosis of recurrence after complete resection in early-stage non-small cell lung cancer. Korean J. Thorac. Cardiovasc Surg. 46:449–456.
42. Luo, J., L. Shen, and D. Zheng. 2014. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci. Rep. 4:6269.
43. Newman, A. M., S. V. Bratman, J. To, J. F. Wynne, N. C. Eclov, L. A. Modlin, et al. 2014. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20:548–554.
44. Vinayanuwattikun, C., P. Winayanuwattikun, P. Chantranuwat, A. Mutirangura, and V. Sriuranpong. 2013. The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 139:67–76.
45. Diehl, F., K. Schmidt, M. A. Choti, K. Romans, S. Goodman, M. Li, et al. 2008. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14:985–990.
46. Spellman, P. T., and J. W. Gray. 2014. Detecting cancer by monitoring circulating tumor DNA. Nat. Med. 20:474–475.
47. Karachaliou, N., C. Mayo-de las Casas, C. Queralt, I. de Aguirre, B. Melloni, F. Cardenal, et al. 2015. Association of EGFR L858R mutation in circulating free DNA With survival in the EURTAC Trial. JAMA Oncol. 1:149–157.
48. Heitzer, E., M. Auer, E. M. Hoffmann, M. Pichler, C. Gasch, P. Ulz, et al. 2013. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int. J. Cancer 133:346–356.
49. Reinert, T., L. V. Scholer, R. Thomsen, H. Tobiasen, S. Vang, I. Nordentoft, et al. 2015. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65:625–634.
50. Nygaard, A. D., P. C. Holdgaard, K. L. G. Spindler, N. Pallisgaard, and A. Jakobsen. 2014. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br. J. Cancer 110:363–368.
51. Kim, K., D. G. Shin, M. K. Park, S. H. Baik, T. H. Kim, S. Kim, et al. 2014. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann. Surg. Treat Res. 86:136–142.
52. Snyder, M. W., M. Kircher, A. J. Hill, R. M. Daza, and J. Shendure. 2016. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164(1–2):57–68.
53. Newman, A. M., S. V. Bratman, J. To, J. F. Wynne, N. C. W. Eclov, L. A. Modlin, et al. 2014. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20:552–558.
54. Ulivi, P., and R. Silvestrini. 2013. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol. 36:439–448.
55. Shaw, J. A., D. S. Guttery, A. Hills, D. Fernandez-Garcia, K. Page, B. M. Rosales, et al. 2016. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts. Clin. Cancer Res. http://clincancerres.aacrjournals.org/content/early/2016/11/03/1078-0432.CCR-16-0825. [Epub ahead of print].
56. Earl, J., S. Garcia-Nieto, J. Carlos Martinez-Avila, J. Montans, A. Sanjuanbenito, and M. Rodriguez-Garrote, et al. 2015. Circulating tumor cells (CTC) and kras mutant circulating free DNA (cf DNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer 15:797.